nodes	percent_of_prediction	percent_of_DWPC	metapath
Methoxsalen—CYP2A6—Fluorouracil—urinary bladder cancer	0.164	0.385	CbGbCtD
Methoxsalen—CYP3A4—Thiotepa—urinary bladder cancer	0.101	0.237	CbGbCtD
Methoxsalen—CYP1A2—Fluorouracil—urinary bladder cancer	0.0625	0.147	CbGbCtD
Methoxsalen—CYP1A2—Etoposide—urinary bladder cancer	0.0522	0.123	CbGbCtD
Methoxsalen—CYP3A4—Etoposide—urinary bladder cancer	0.0273	0.0643	CbGbCtD
Methoxsalen—CYP3A4—Doxorubicin—urinary bladder cancer	0.0187	0.0438	CbGbCtD
Methoxsalen—Device related infection—Fluorouracil—urinary bladder cancer	0.014	0.0524	CcSEcCtD
Methoxsalen—Leukoderma—Thiotepa—urinary bladder cancer	0.00689	0.0258	CcSEcCtD
Methoxsalen—Skin hyperpigmentation—Thiotepa—urinary bladder cancer	0.00492	0.0185	CcSEcCtD
Methoxsalen—Sunburn—Methotrexate—urinary bladder cancer	0.00417	0.0157	CcSEcCtD
Methoxsalen—Skin hyperpigmentation—Fluorouracil—urinary bladder cancer	0.00407	0.0153	CcSEcCtD
Methoxsalen—Ill-defined disorder—Valrubicin—urinary bladder cancer	0.00343	0.0129	CcSEcCtD
Methoxsalen—Blister—Fluorouracil—urinary bladder cancer	0.00336	0.0126	CcSEcCtD
Methoxsalen—Malaise—Valrubicin—urinary bladder cancer	0.00333	0.0125	CcSEcCtD
Methoxsalen—Discomfort—Valrubicin—urinary bladder cancer	0.00311	0.0117	CcSEcCtD
Methoxsalen—Leukoderma—Methotrexate—urinary bladder cancer	0.00296	0.0111	CcSEcCtD
Methoxsalen—Tenderness—Gemcitabine—urinary bladder cancer	0.00282	0.0106	CcSEcCtD
Methoxsalen—Skin exfoliation—Thiotepa—urinary bladder cancer	0.00279	0.0105	CcSEcCtD
Methoxsalen—Tenderness—Fluorouracil—urinary bladder cancer	0.00278	0.0104	CcSEcCtD
Methoxsalen—Infection—Carboplatin—urinary bladder cancer	0.00277	0.0104	CcSEcCtD
Methoxsalen—Leukoderma—Epirubicin—urinary bladder cancer	0.00277	0.0104	CcSEcCtD
Methoxsalen—Tenderness—Cisplatin—urinary bladder cancer	0.00263	0.00988	CcSEcCtD
Methoxsalen—Herpes simplex—Fluorouracil—urinary bladder cancer	0.00263	0.00986	CcSEcCtD
Methoxsalen—Leukoderma—Doxorubicin—urinary bladder cancer	0.00257	0.00963	CcSEcCtD
Methoxsalen—Erythema—Mitomycin—urinary bladder cancer	0.00254	0.00955	CcSEcCtD
Methoxsalen—Inflammation—Fluorouracil—urinary bladder cancer	0.0025	0.00937	CcSEcCtD
Methoxsalen—Feeling abnormal—Valrubicin—urinary bladder cancer	0.00248	0.00933	CcSEcCtD
Methoxsalen—Body temperature increased—Valrubicin—urinary bladder cancer	0.00238	0.00895	CcSEcCtD
Methoxsalen—Ill-defined disorder—Mitomycin—urinary bladder cancer	0.00236	0.00886	CcSEcCtD
Methoxsalen—Skin exfoliation—Gemcitabine—urinary bladder cancer	0.00235	0.00883	CcSEcCtD
Methoxsalen—Malaise—Mitomycin—urinary bladder cancer	0.00229	0.00861	CcSEcCtD
Methoxsalen—Body temperature increased—Carboplatin—urinary bladder cancer	0.00221	0.00828	CcSEcCtD
Methoxsalen—Skin exfoliation—Cisplatin—urinary bladder cancer	0.00219	0.00823	CcSEcCtD
Methoxsalen—Inflammation—Etoposide—urinary bladder cancer	0.00217	0.00814	CcSEcCtD
Methoxsalen—Discomfort—Mitomycin—urinary bladder cancer	0.00214	0.00803	CcSEcCtD
Methoxsalen—Pruritus—Valrubicin—urinary bladder cancer	0.00213	0.00801	CcSEcCtD
Methoxsalen—Skin hyperpigmentation—Methotrexate—urinary bladder cancer	0.00212	0.00795	CcSEcCtD
Methoxsalen—Oedema—Mitomycin—urinary bladder cancer	0.00208	0.0078	CcSEcCtD
Methoxsalen—Skin exfoliation—Etoposide—urinary bladder cancer	0.00201	0.00754	CcSEcCtD
Methoxsalen—Folliculitis—Methotrexate—urinary bladder cancer	0.002	0.00752	CcSEcCtD
Methoxsalen—Dizziness—Valrubicin—urinary bladder cancer	0.00199	0.00748	CcSEcCtD
Methoxsalen—Skin hyperpigmentation—Epirubicin—urinary bladder cancer	0.00198	0.00744	CcSEcCtD
Methoxsalen—Rash—Valrubicin—urinary bladder cancer	0.0019	0.00714	CcSEcCtD
Methoxsalen—Dermatitis—Valrubicin—urinary bladder cancer	0.0019	0.00713	CcSEcCtD
Methoxsalen—Headache—Valrubicin—urinary bladder cancer	0.00189	0.00709	CcSEcCtD
Methoxsalen—Folliculitis—Epirubicin—urinary bladder cancer	0.00188	0.00704	CcSEcCtD
Methoxsalen—Dermatitis bullous—Gemcitabine—urinary bladder cancer	0.00187	0.00702	CcSEcCtD
Methoxsalen—Dermatitis bullous—Fluorouracil—urinary bladder cancer	0.00184	0.0069	CcSEcCtD
Methoxsalen—Skin hyperpigmentation—Doxorubicin—urinary bladder cancer	0.00183	0.00688	CcSEcCtD
Methoxsalen—Nausea—Valrubicin—urinary bladder cancer	0.00179	0.00672	CcSEcCtD
Methoxsalen—Redness—Epirubicin—urinary bladder cancer	0.00175	0.00655	CcSEcCtD
Methoxsalen—Folliculitis—Doxorubicin—urinary bladder cancer	0.00174	0.00651	CcSEcCtD
Methoxsalen—Feeling abnormal—Mitomycin—urinary bladder cancer	0.00171	0.00642	CcSEcCtD
Methoxsalen—Body temperature increased—Mitomycin—urinary bladder cancer	0.00164	0.00616	CcSEcCtD
Methoxsalen—Blister—Epirubicin—urinary bladder cancer	0.00164	0.00614	CcSEcCtD
Methoxsalen—Redness—Doxorubicin—urinary bladder cancer	0.00162	0.00606	CcSEcCtD
Methoxsalen—Dry skin—Fluorouracil—urinary bladder cancer	0.00161	0.00605	CcSEcCtD
Methoxsalen—Blister—Doxorubicin—urinary bladder cancer	0.00151	0.00568	CcSEcCtD
Methoxsalen—CYP1A2—urine—urinary bladder cancer	0.00141	0.196	CbGeAlD
Methoxsalen—Photosensitivity reaction—Fluorouracil—urinary bladder cancer	0.00139	0.0052	CcSEcCtD
Methoxsalen—Dizziness—Mitomycin—urinary bladder cancer	0.00137	0.00516	CcSEcCtD
Methoxsalen—Herpes simplex—Methotrexate—urinary bladder cancer	0.00137	0.00513	CcSEcCtD
Methoxsalen—Arrhythmia—Thiotepa—urinary bladder cancer	0.00131	0.00493	CcSEcCtD
Methoxsalen—Rash—Mitomycin—urinary bladder cancer	0.00131	0.00492	CcSEcCtD
Methoxsalen—Dermatitis—Mitomycin—urinary bladder cancer	0.00131	0.00491	CcSEcCtD
Methoxsalen—Headache—Mitomycin—urinary bladder cancer	0.0013	0.00488	CcSEcCtD
Methoxsalen—Inflammation—Methotrexate—urinary bladder cancer	0.0013	0.00487	CcSEcCtD
Methoxsalen—Erythema—Thiotepa—urinary bladder cancer	0.00128	0.0048	CcSEcCtD
Methoxsalen—Herpes simplex—Epirubicin—urinary bladder cancer	0.00128	0.0048	CcSEcCtD
Methoxsalen—Tension—Thiotepa—urinary bladder cancer	0.00126	0.00471	CcSEcCtD
Methoxsalen—Nervousness—Thiotepa—urinary bladder cancer	0.00124	0.00467	CcSEcCtD
Methoxsalen—Nausea—Mitomycin—urinary bladder cancer	0.00123	0.00463	CcSEcCtD
Methoxsalen—Inflammation—Epirubicin—urinary bladder cancer	0.00122	0.00456	CcSEcCtD
Methoxsalen—Skin exfoliation—Methotrexate—urinary bladder cancer	0.0012	0.00451	CcSEcCtD
Methoxsalen—Herpes simplex—Doxorubicin—urinary bladder cancer	0.00118	0.00444	CcSEcCtD
Methoxsalen—Skin exfoliation—Epirubicin—urinary bladder cancer	0.00113	0.00422	CcSEcCtD
Methoxsalen—Inflammation—Doxorubicin—urinary bladder cancer	0.00112	0.00422	CcSEcCtD
Methoxsalen—Arrhythmia—Gemcitabine—urinary bladder cancer	0.0011	0.00415	CcSEcCtD
Methoxsalen—Arrhythmia—Fluorouracil—urinary bladder cancer	0.00109	0.00408	CcSEcCtD
Methoxsalen—Cramps of lower extremities—Epirubicin—urinary bladder cancer	0.00108	0.00406	CcSEcCtD
Methoxsalen—Erythema—Gemcitabine—urinary bladder cancer	0.00108	0.00404	CcSEcCtD
Methoxsalen—Erythema—Fluorouracil—urinary bladder cancer	0.00106	0.00397	CcSEcCtD
Methoxsalen—Skin exfoliation—Doxorubicin—urinary bladder cancer	0.00104	0.00391	CcSEcCtD
Methoxsalen—Infection—Thiotepa—urinary bladder cancer	0.00104	0.00389	CcSEcCtD
Methoxsalen—Arrhythmia—Cisplatin—urinary bladder cancer	0.00103	0.00387	CcSEcCtD
Methoxsalen—CYP3A4—urine—urinary bladder cancer	0.00102	0.142	CbGeAlD
Methoxsalen—Skin disorder—Thiotepa—urinary bladder cancer	0.00101	0.00381	CcSEcCtD
Methoxsalen—Erythema—Cisplatin—urinary bladder cancer	0.001	0.00377	CcSEcCtD
Methoxsalen—Cramps of lower extremities—Doxorubicin—urinary bladder cancer	0.001	0.00376	CcSEcCtD
Methoxsalen—Ill-defined disorder—Gemcitabine—urinary bladder cancer	0.000999	0.00375	CcSEcCtD
Methoxsalen—Malaise—Gemcitabine—urinary bladder cancer	0.000971	0.00364	CcSEcCtD
Methoxsalen—Muscle spasms—Cisplatin—urinary bladder cancer	0.000965	0.00362	CcSEcCtD
Methoxsalen—CYP2A6—prostate gland—urinary bladder cancer	0.000961	0.134	CbGeAlD
Methoxsalen—Ill-defined disorder—Cisplatin—urinary bladder cancer	0.000931	0.00349	CcSEcCtD
Methoxsalen—Dyspepsia—Thiotepa—urinary bladder cancer	0.000919	0.00345	CcSEcCtD
Methoxsalen—Discomfort—Gemcitabine—urinary bladder cancer	0.000905	0.0034	CcSEcCtD
Methoxsalen—Malaise—Cisplatin—urinary bladder cancer	0.000905	0.0034	CcSEcCtD
Methoxsalen—Gastrointestinal disorder—Thiotepa—urinary bladder cancer	0.000902	0.00338	CcSEcCtD
Methoxsalen—Dysgeusia—Etoposide—urinary bladder cancer	0.0009	0.00338	CcSEcCtD
Methoxsalen—Dermatitis bullous—Epirubicin—urinary bladder cancer	0.000895	0.00336	CcSEcCtD
Methoxsalen—Discomfort—Fluorouracil—urinary bladder cancer	0.00089	0.00334	CcSEcCtD
Methoxsalen—Muscle spasms—Etoposide—urinary bladder cancer	0.000884	0.00332	CcSEcCtD
Methoxsalen—Oedema—Gemcitabine—urinary bladder cancer	0.000879	0.0033	CcSEcCtD
Methoxsalen—Infection—Gemcitabine—urinary bladder cancer	0.000873	0.00328	CcSEcCtD
Methoxsalen—Oedema—Fluorouracil—urinary bladder cancer	0.000864	0.00324	CcSEcCtD
Methoxsalen—Feeling abnormal—Thiotepa—urinary bladder cancer	0.000861	0.00323	CcSEcCtD
Methoxsalen—Infection—Fluorouracil—urinary bladder cancer	0.000858	0.00322	CcSEcCtD
Methoxsalen—Skin disorder—Gemcitabine—urinary bladder cancer	0.000853	0.0032	CcSEcCtD
Methoxsalen—Ill-defined disorder—Etoposide—urinary bladder cancer	0.000853	0.0032	CcSEcCtD
Methoxsalen—Discomfort—Cisplatin—urinary bladder cancer	0.000844	0.00317	CcSEcCtD
Methoxsalen—Urticaria—Thiotepa—urinary bladder cancer	0.00083	0.00311	CcSEcCtD
Methoxsalen—Malaise—Etoposide—urinary bladder cancer	0.000829	0.00311	CcSEcCtD
Methoxsalen—Dermatitis bullous—Doxorubicin—urinary bladder cancer	0.000828	0.00311	CcSEcCtD
Methoxsalen—Vertigo—Etoposide—urinary bladder cancer	0.000826	0.0031	CcSEcCtD
Methoxsalen—Body temperature increased—Thiotepa—urinary bladder cancer	0.000826	0.0031	CcSEcCtD
Methoxsalen—Hypotension—Gemcitabine—urinary bladder cancer	0.000821	0.00308	CcSEcCtD
Methoxsalen—Oedema—Cisplatin—urinary bladder cancer	0.000819	0.00307	CcSEcCtD
Methoxsalen—Infection—Cisplatin—urinary bladder cancer	0.000814	0.00305	CcSEcCtD
Methoxsalen—CYP2A6—seminal vesicle—urinary bladder cancer	0.000813	0.113	CbGeAlD
Methoxsalen—Hypotension—Fluorouracil—urinary bladder cancer	0.000807	0.00303	CcSEcCtD
Methoxsalen—Skin disorder—Cisplatin—urinary bladder cancer	0.000795	0.00299	CcSEcCtD
Methoxsalen—Insomnia—Gemcitabine—urinary bladder cancer	0.000795	0.00298	CcSEcCtD
Methoxsalen—Dry skin—Epirubicin—urinary bladder cancer	0.000784	0.00294	CcSEcCtD
Methoxsalen—Insomnia—Fluorouracil—urinary bladder cancer	0.000781	0.00293	CcSEcCtD
Methoxsalen—Discomfort—Etoposide—urinary bladder cancer	0.000773	0.0029	CcSEcCtD
Methoxsalen—Hypersensitivity—Thiotepa—urinary bladder cancer	0.000769	0.00289	CcSEcCtD
Methoxsalen—Hypotension—Cisplatin—urinary bladder cancer	0.000765	0.00287	CcSEcCtD
Methoxsalen—Dyspepsia—Fluorouracil—urinary bladder cancer	0.00076	0.00285	CcSEcCtD
Methoxsalen—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.000758	0.00285	CcSEcCtD
Methoxsalen—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.000746	0.0028	CcSEcCtD
Methoxsalen—Infection—Etoposide—urinary bladder cancer	0.000745	0.0028	CcSEcCtD
Methoxsalen—Pruritus—Thiotepa—urinary bladder cancer	0.000739	0.00277	CcSEcCtD
Methoxsalen—Skin disorder—Etoposide—urinary bladder cancer	0.000729	0.00274	CcSEcCtD
Methoxsalen—Dry skin—Doxorubicin—urinary bladder cancer	0.000726	0.00272	CcSEcCtD
Methoxsalen—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.000724	0.00272	CcSEcCtD
Methoxsalen—Photosensitivity reaction—Methotrexate—urinary bladder cancer	0.000721	0.00271	CcSEcCtD
Methoxsalen—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.000712	0.00267	CcSEcCtD
Methoxsalen—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000707	0.00265	CcSEcCtD
Methoxsalen—Depression—Methotrexate—urinary bladder cancer	0.000703	0.00264	CcSEcCtD
Methoxsalen—Hypotension—Etoposide—urinary bladder cancer	0.000701	0.00263	CcSEcCtD
Methoxsalen—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000695	0.00261	CcSEcCtD
Methoxsalen—Dizziness—Thiotepa—urinary bladder cancer	0.000691	0.00259	CcSEcCtD
Methoxsalen—Urticaria—Fluorouracil—urinary bladder cancer	0.000686	0.00258	CcSEcCtD
Methoxsalen—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000683	0.00256	CcSEcCtD
Methoxsalen—Photosensitivity reaction—Epirubicin—urinary bladder cancer	0.000675	0.00253	CcSEcCtD
Methoxsalen—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000675	0.00253	CcSEcCtD
Methoxsalen—Rash—Thiotepa—urinary bladder cancer	0.000659	0.00247	CcSEcCtD
Methoxsalen—Dermatitis—Thiotepa—urinary bladder cancer	0.000658	0.00247	CcSEcCtD
Methoxsalen—Headache—Thiotepa—urinary bladder cancer	0.000654	0.00246	CcSEcCtD
Methoxsalen—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000648	0.00243	CcSEcCtD
Methoxsalen—Body temperature increased—Cisplatin—urinary bladder cancer	0.000647	0.00243	CcSEcCtD
Methoxsalen—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000636	0.00239	CcSEcCtD
Methoxsalen—Photosensitivity reaction—Doxorubicin—urinary bladder cancer	0.000625	0.00234	CcSEcCtD
Methoxsalen—Pruritus—Gemcitabine—urinary bladder cancer	0.000622	0.00233	CcSEcCtD
Methoxsalen—Nausea—Thiotepa—urinary bladder cancer	0.00062	0.00233	CcSEcCtD
Methoxsalen—Feeling abnormal—Etoposide—urinary bladder cancer	0.000618	0.00232	CcSEcCtD
Methoxsalen—Pruritus—Fluorouracil—urinary bladder cancer	0.000611	0.00229	CcSEcCtD
Methoxsalen—CYP1A1—Arachidonic acid metabolism—GPX1—urinary bladder cancer	0.000603	0.002	CbGpPWpGaD
Methoxsalen—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000603	0.00226	CcSEcCtD
Methoxsalen—Urticaria—Etoposide—urinary bladder cancer	0.000596	0.00224	CcSEcCtD
Methoxsalen—Body temperature increased—Etoposide—urinary bladder cancer	0.000593	0.00223	CcSEcCtD
Methoxsalen—CYP1A2—Biological oxidations—GSTZ1—urinary bladder cancer	0.000583	0.00194	CbGpPWpGaD
Methoxsalen—CYP2A13—Metabolism—SLC19A1—urinary bladder cancer	0.000577	0.00192	CbGpPWpGaD
Methoxsalen—CYP1A2—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000575	0.00191	CbGpPWpGaD
Methoxsalen—Dizziness—Fluorouracil—urinary bladder cancer	0.000571	0.00214	CcSEcCtD
Methoxsalen—CYP2A13—Metabolism—PRSS3—urinary bladder cancer	0.000562	0.00187	CbGpPWpGaD
Methoxsalen—CYP1A2—Aryl Hydrocarbon Receptor Pathway—NQO1—urinary bladder cancer	0.00056	0.00186	CbGpPWpGaD
Methoxsalen—CYP1A2—Aryl Hydrocarbon Receptor—NQO1—urinary bladder cancer	0.00056	0.00186	CbGpPWpGaD
Methoxsalen—Rash—Gemcitabine—urinary bladder cancer	0.000554	0.00208	CcSEcCtD
Methoxsalen—Dermatitis—Gemcitabine—urinary bladder cancer	0.000553	0.00208	CcSEcCtD
Methoxsalen—Hypersensitivity—Etoposide—urinary bladder cancer	0.000553	0.00207	CcSEcCtD
Methoxsalen—CYP1A2—Biological oxidations—GSTO2—urinary bladder cancer	0.000553	0.00184	CbGpPWpGaD
Methoxsalen—CYP1A2—Biological oxidations—NAT1—urinary bladder cancer	0.000553	0.00184	CbGpPWpGaD
Methoxsalen—Erythema—Methotrexate—urinary bladder cancer	0.000551	0.00207	CcSEcCtD
Methoxsalen—Headache—Gemcitabine—urinary bladder cancer	0.00055	0.00207	CcSEcCtD
Methoxsalen—CYP1A2—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000545	0.00181	CbGpPWpGaD
Methoxsalen—Rash—Fluorouracil—urinary bladder cancer	0.000545	0.00204	CcSEcCtD
Methoxsalen—Dermatitis—Fluorouracil—urinary bladder cancer	0.000544	0.00204	CcSEcCtD
Methoxsalen—Headache—Fluorouracil—urinary bladder cancer	0.000541	0.00203	CcSEcCtD
Methoxsalen—Dysgeusia—Methotrexate—urinary bladder cancer	0.000539	0.00202	CcSEcCtD
Methoxsalen—Pruritus—Etoposide—urinary bladder cancer	0.000531	0.00199	CcSEcCtD
Methoxsalen—CYP1A1—Aryl Hydrocarbon Receptor—ESR1—urinary bladder cancer	0.000529	0.00176	CbGpPWpGaD
Methoxsalen—Arrhythmia—Epirubicin—urinary bladder cancer	0.000529	0.00198	CcSEcCtD
Methoxsalen—Nausea—Gemcitabine—urinary bladder cancer	0.000522	0.00196	CcSEcCtD
Methoxsalen—CYP1A2—Phase II conjugation—NAT2—urinary bladder cancer	0.000517	0.00172	CbGpPWpGaD
Methoxsalen—Rash—Cisplatin—urinary bladder cancer	0.000516	0.00194	CcSEcCtD
Methoxsalen—Dermatitis—Cisplatin—urinary bladder cancer	0.000516	0.00194	CcSEcCtD
Methoxsalen—Erythema—Epirubicin—urinary bladder cancer	0.000515	0.00193	CcSEcCtD
Methoxsalen—Nausea—Fluorouracil—urinary bladder cancer	0.000513	0.00193	CcSEcCtD
Methoxsalen—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000511	0.00192	CcSEcCtD
Methoxsalen—CYP2A6—Biological oxidations—HPGDS—urinary bladder cancer	0.000509	0.00169	CbGpPWpGaD
Methoxsalen—Tension—Epirubicin—urinary bladder cancer	0.000506	0.0019	CcSEcCtD
Methoxsalen—CYP1A2—Biological oxidations—UGT2B7—urinary bladder cancer	0.000505	0.00168	CbGpPWpGaD
Methoxsalen—Dysgeusia—Epirubicin—urinary bladder cancer	0.000505	0.00189	CcSEcCtD
Methoxsalen—Nervousness—Epirubicin—urinary bladder cancer	0.0005	0.00188	CcSEcCtD
Methoxsalen—CYP1A2—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000498	0.00166	CbGpPWpGaD
Methoxsalen—Malaise—Methotrexate—urinary bladder cancer	0.000497	0.00186	CcSEcCtD
Methoxsalen—Dizziness—Etoposide—urinary bladder cancer	0.000496	0.00186	CcSEcCtD
Methoxsalen—Muscle spasms—Epirubicin—urinary bladder cancer	0.000495	0.00186	CcSEcCtD
Methoxsalen—Vertigo—Methotrexate—urinary bladder cancer	0.000495	0.00186	CcSEcCtD
Methoxsalen—CYP2A6—Biological oxidations—GSTT1—urinary bladder cancer	0.000494	0.00164	CbGpPWpGaD
Methoxsalen—Arrhythmia—Doxorubicin—urinary bladder cancer	0.000489	0.00184	CcSEcCtD
Methoxsalen—Nausea—Cisplatin—urinary bladder cancer	0.000486	0.00183	CcSEcCtD
Methoxsalen—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000478	0.00179	CcSEcCtD
Methoxsalen—Erythema—Doxorubicin—urinary bladder cancer	0.000477	0.00179	CcSEcCtD
Methoxsalen—CYP1A1—Biological oxidations—NAT2—urinary bladder cancer	0.000475	0.00158	CbGpPWpGaD
Methoxsalen—CYP2A6—vagina—urinary bladder cancer	0.000474	0.0661	CbGeAlD
Methoxsalen—Rash—Etoposide—urinary bladder cancer	0.000473	0.00178	CcSEcCtD
Methoxsalen—Dermatitis—Etoposide—urinary bladder cancer	0.000473	0.00177	CcSEcCtD
Methoxsalen—Headache—Etoposide—urinary bladder cancer	0.00047	0.00176	CcSEcCtD
Methoxsalen—CYP1A1—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000468	0.00156	CbGpPWpGaD
Methoxsalen—CYP2A6—NRF2 pathway—NQO1—urinary bladder cancer	0.000468	0.00156	CbGpPWpGaD
Methoxsalen—Tension—Doxorubicin—urinary bladder cancer	0.000468	0.00176	CcSEcCtD
Methoxsalen—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000467	0.00175	CcSEcCtD
Methoxsalen—Malaise—Epirubicin—urinary bladder cancer	0.000465	0.00174	CcSEcCtD
Methoxsalen—Discomfort—Methotrexate—urinary bladder cancer	0.000463	0.00174	CcSEcCtD
Methoxsalen—Nervousness—Doxorubicin—urinary bladder cancer	0.000463	0.00174	CcSEcCtD
Methoxsalen—Vertigo—Epirubicin—urinary bladder cancer	0.000463	0.00174	CcSEcCtD
Methoxsalen—CYP1A1—Aryl Hydrocarbon Receptor—RB1—urinary bladder cancer	0.000462	0.00153	CbGpPWpGaD
Methoxsalen—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000458	0.00172	CcSEcCtD
Methoxsalen—CYP1A2—Biological oxidations—CYP4B1—urinary bladder cancer	0.000455	0.00151	CbGpPWpGaD
Methoxsalen—CYP3A4—Biological oxidations—GSTZ1—urinary bladder cancer	0.00045	0.00149	CbGpPWpGaD
Methoxsalen—CYP2A13—Metabolism—TYMP—urinary bladder cancer	0.000449	0.00149	CbGpPWpGaD
Methoxsalen—CYP1A2—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000449	0.00149	CbGpPWpGaD
Methoxsalen—Infection—Methotrexate—urinary bladder cancer	0.000446	0.00168	CcSEcCtD
Methoxsalen—Nausea—Etoposide—urinary bladder cancer	0.000446	0.00167	CcSEcCtD
Methoxsalen—CYP3A4—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000444	0.00147	CbGpPWpGaD
Methoxsalen—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000442	0.00166	CcSEcCtD
Methoxsalen—Skin disorder—Methotrexate—urinary bladder cancer	0.000436	0.00164	CcSEcCtD
Methoxsalen—Discomfort—Epirubicin—urinary bladder cancer	0.000433	0.00163	CcSEcCtD
Methoxsalen—Malaise—Doxorubicin—urinary bladder cancer	0.00043	0.00161	CcSEcCtD
Methoxsalen—Vertigo—Doxorubicin—urinary bladder cancer	0.000428	0.00161	CcSEcCtD
Methoxsalen—CYP3A4—Biological oxidations—NAT1—urinary bladder cancer	0.000426	0.00142	CbGpPWpGaD
Methoxsalen—CYP3A4—Biological oxidations—GSTO2—urinary bladder cancer	0.000426	0.00142	CbGpPWpGaD
Methoxsalen—CYP3A4—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000421	0.0014	CbGpPWpGaD
Methoxsalen—Oedema—Epirubicin—urinary bladder cancer	0.000421	0.00158	CcSEcCtD
Methoxsalen—Hypotension—Methotrexate—urinary bladder cancer	0.00042	0.00158	CcSEcCtD
Methoxsalen—Infection—Epirubicin—urinary bladder cancer	0.000418	0.00157	CcSEcCtD
Methoxsalen—CYP1A2—Phase II conjugation—HPGDS—urinary bladder cancer	0.000414	0.00137	CbGpPWpGaD
Methoxsalen—Skin disorder—Epirubicin—urinary bladder cancer	0.000408	0.00153	CcSEcCtD
Methoxsalen—Insomnia—Methotrexate—urinary bladder cancer	0.000406	0.00153	CcSEcCtD
Methoxsalen—CYP2A13—Metabolism—NAT2—urinary bladder cancer	0.000406	0.00135	CbGpPWpGaD
Methoxsalen—CYP1A2—Phase II conjugation—GSTT1—urinary bladder cancer	0.000401	0.00133	CbGpPWpGaD
Methoxsalen—Discomfort—Doxorubicin—urinary bladder cancer	0.000401	0.00151	CcSEcCtD
Methoxsalen—CYP2A6—Fluoropyrimidine Activity—TP53—urinary bladder cancer	0.000396	0.00131	CbGpPWpGaD
Methoxsalen—Dyspepsia—Methotrexate—urinary bladder cancer	0.000396	0.00148	CcSEcCtD
Methoxsalen—Hypotension—Epirubicin—urinary bladder cancer	0.000393	0.00148	CcSEcCtD
Methoxsalen—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000392	0.0013	CbGpPWpGaD
Methoxsalen—CYP2A6—NRF2 pathway—GSTP1—urinary bladder cancer	0.00039	0.0013	CbGpPWpGaD
Methoxsalen—CYP3A4—Biological oxidations—UGT2B7—urinary bladder cancer	0.00039	0.0013	CbGpPWpGaD
Methoxsalen—Oedema—Doxorubicin—urinary bladder cancer	0.000389	0.00146	CcSEcCtD
Methoxsalen—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000388	0.00146	CcSEcCtD
Methoxsalen—Infection—Doxorubicin—urinary bladder cancer	0.000387	0.00145	CcSEcCtD
Methoxsalen—CYP1A2—Arachidonic acid metabolism—GPX1—urinary bladder cancer	0.000385	0.00128	CbGpPWpGaD
Methoxsalen—CYP3A4—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000385	0.00128	CbGpPWpGaD
Methoxsalen—Insomnia—Epirubicin—urinary bladder cancer	0.00038	0.00143	CcSEcCtD
Methoxsalen—CYP1A1—Aryl Hydrocarbon Receptor—PTGS2—urinary bladder cancer	0.00038	0.00126	CbGpPWpGaD
Methoxsalen—CYP1A1—Biological oxidations—HPGDS—urinary bladder cancer	0.00038	0.00126	CbGpPWpGaD
Methoxsalen—Skin disorder—Doxorubicin—urinary bladder cancer	0.000378	0.00142	CcSEcCtD
Methoxsalen—Feeling abnormal—Methotrexate—urinary bladder cancer	0.00037	0.00139	CcSEcCtD
Methoxsalen—Dyspepsia—Epirubicin—urinary bladder cancer	0.00037	0.00139	CcSEcCtD
Methoxsalen—CYP1A1—Biological oxidations—GSTT1—urinary bladder cancer	0.000368	0.00122	CbGpPWpGaD
Methoxsalen—CYP1A1—epithelium—urinary bladder cancer	0.000366	0.051	CbGeAlD
Methoxsalen—Hypotension—Doxorubicin—urinary bladder cancer	0.000364	0.00136	CcSEcCtD
Methoxsalen—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000363	0.00136	CcSEcCtD
Methoxsalen—CYP2A6—NRF2 pathway—GSTM1—urinary bladder cancer	0.000359	0.00119	CbGpPWpGaD
Methoxsalen—Urticaria—Methotrexate—urinary bladder cancer	0.000357	0.00134	CcSEcCtD
Methoxsalen—Body temperature increased—Methotrexate—urinary bladder cancer	0.000355	0.00133	CcSEcCtD
Methoxsalen—CYP1A1—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.000355	0.00118	CbGpPWpGaD
Methoxsalen—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL2—urinary bladder cancer	0.000352	0.00117	CbGpPWpGaD
Methoxsalen—Insomnia—Doxorubicin—urinary bladder cancer	0.000352	0.00132	CcSEcCtD
Methoxsalen—CYP3A4—Biological oxidations—CYP4B1—urinary bladder cancer	0.000351	0.00117	CbGpPWpGaD
Methoxsalen—CYP2A13—Metabolism—RRM2—urinary bladder cancer	0.000351	0.00117	CbGpPWpGaD
Methoxsalen—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000347	0.0013	CcSEcCtD
Methoxsalen—CYP3A4—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000346	0.00115	CbGpPWpGaD
Methoxsalen—CYP1A2—renal system—urinary bladder cancer	0.000344	0.0479	CbGeAlD
Methoxsalen—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000343	0.00129	CcSEcCtD
Methoxsalen—CYP2A6—Biological oxidations—GSTP1—urinary bladder cancer	0.000342	0.00114	CbGpPWpGaD
Methoxsalen—CYP1A1—renal system—urinary bladder cancer	0.000339	0.0473	CbGeAlD
Methoxsalen—CYP1A2—Aryl Hydrocarbon Receptor—ESR1—urinary bladder cancer	0.000337	0.00112	CbGpPWpGaD
Methoxsalen—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000336	0.00126	CcSEcCtD
Methoxsalen—CYP1A1—PPARA activates gene expression—NCOR1—urinary bladder cancer	0.000335	0.00111	CbGpPWpGaD
Methoxsalen—Urticaria—Epirubicin—urinary bladder cancer	0.000334	0.00125	CcSEcCtD
Methoxsalen—CYP1A1—urethra—urinary bladder cancer	0.000333	0.0464	CbGeAlD
Methoxsalen—Body temperature increased—Epirubicin—urinary bladder cancer	0.000332	0.00125	CcSEcCtD
Methoxsalen—CYP1A1—Aryl Hydrocarbon Receptor—CDKN1A—urinary bladder cancer	0.000332	0.0011	CbGpPWpGaD
Methoxsalen—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000331	0.00124	CcSEcCtD
Methoxsalen—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—NCOR1—urinary bladder cancer	0.000328	0.00109	CbGpPWpGaD
Methoxsalen—CYP2A13—Metabolism—HPGDS—urinary bladder cancer	0.000325	0.00108	CbGpPWpGaD
Methoxsalen—CYP2A13—Metabolism—ENO2—urinary bladder cancer	0.000325	0.00108	CbGpPWpGaD
Methoxsalen—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000321	0.0012	CcSEcCtD
Methoxsalen—Pruritus—Methotrexate—urinary bladder cancer	0.000318	0.00119	CcSEcCtD
Methoxsalen—CYP1A1—Aryl Hydrocarbon Receptor—EP300—urinary bladder cancer	0.000316	0.00105	CbGpPWpGaD
Methoxsalen—CYP1A1—Aryl Hydrocarbon Receptor Pathway—EP300—urinary bladder cancer	0.000316	0.00105	CbGpPWpGaD
Methoxsalen—CYP2A13—Metabolism—GSTT1—urinary bladder cancer	0.000315	0.00105	CbGpPWpGaD
Methoxsalen—CYP2A6—Biological oxidations—GSTM1—urinary bladder cancer	0.000315	0.00105	CbGpPWpGaD
Methoxsalen—Hypersensitivity—Epirubicin—urinary bladder cancer	0.00031	0.00116	CcSEcCtD
Methoxsalen—Urticaria—Doxorubicin—urinary bladder cancer	0.000309	0.00116	CcSEcCtD
Methoxsalen—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000308	0.00115	CcSEcCtD
Methoxsalen—CYP1A1—Aryl Hydrocarbon Receptor Pathway—SRC—urinary bladder cancer	0.000307	0.00102	CbGpPWpGaD
Methoxsalen—CYP1A1—Aryl Hydrocarbon Receptor—SRC—urinary bladder cancer	0.000307	0.00102	CbGpPWpGaD
Methoxsalen—CYP1A2—Biological oxidations—NAT2—urinary bladder cancer	0.000303	0.00101	CbGpPWpGaD
Methoxsalen—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000303	0.001	CbGpPWpGaD
Methoxsalen—CYP1A2—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000299	0.000992	CbGpPWpGaD
Methoxsalen—Pruritus—Epirubicin—urinary bladder cancer	0.000298	0.00112	CcSEcCtD
Methoxsalen—Dizziness—Methotrexate—urinary bladder cancer	0.000297	0.00112	CcSEcCtD
Methoxsalen—CYP1A2—Aryl Hydrocarbon Receptor—RB1—urinary bladder cancer	0.000295	0.000979	CbGpPWpGaD
Methoxsalen—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000287	0.00108	CcSEcCtD
Methoxsalen—Rash—Methotrexate—urinary bladder cancer	0.000283	0.00106	CcSEcCtD
Methoxsalen—Dermatitis—Methotrexate—urinary bladder cancer	0.000283	0.00106	CcSEcCtD
Methoxsalen—Headache—Methotrexate—urinary bladder cancer	0.000282	0.00106	CcSEcCtD
Methoxsalen—CYP1A2—Phase II conjugation—GSTP1—urinary bladder cancer	0.000278	0.000924	CbGpPWpGaD
Methoxsalen—Dizziness—Epirubicin—urinary bladder cancer	0.000278	0.00104	CcSEcCtD
Methoxsalen—Pruritus—Doxorubicin—urinary bladder cancer	0.000275	0.00103	CcSEcCtD
Methoxsalen—CYP1A1—Aryl Hydrocarbon Receptor—MYC—urinary bladder cancer	0.000275	0.000914	CbGpPWpGaD
Methoxsalen—CYP1A1—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000274	0.00091	CbGpPWpGaD
Methoxsalen—CYP1A1—female reproductive system—urinary bladder cancer	0.000272	0.0379	CbGeAlD
Methoxsalen—CYP1A1—Aryl Hydrocarbon Receptor—EGFR—urinary bladder cancer	0.000269	0.000894	CbGpPWpGaD
Methoxsalen—CYP1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—urinary bladder cancer	0.000269	0.000894	CbGpPWpGaD
Methoxsalen—Nausea—Methotrexate—urinary bladder cancer	0.000267	0.001	CcSEcCtD
Methoxsalen—Rash—Epirubicin—urinary bladder cancer	0.000265	0.000995	CcSEcCtD
Methoxsalen—Dermatitis—Epirubicin—urinary bladder cancer	0.000265	0.000994	CcSEcCtD
Methoxsalen—Headache—Epirubicin—urinary bladder cancer	0.000263	0.000989	CcSEcCtD
Methoxsalen—CYP2A13—Metabolism—NQO1—urinary bladder cancer	0.000262	0.00087	CbGpPWpGaD
Methoxsalen—Dizziness—Doxorubicin—urinary bladder cancer	0.000257	0.000966	CcSEcCtD
Methoxsalen—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TNF—urinary bladder cancer	0.000256	0.000852	CbGpPWpGaD
Methoxsalen—CYP1A1—Aryl Hydrocarbon Receptor—TNF—urinary bladder cancer	0.000256	0.000852	CbGpPWpGaD
Methoxsalen—CYP1A2—Phase II conjugation—GSTM1—urinary bladder cancer	0.000256	0.000849	CbGpPWpGaD
Methoxsalen—CYP1A1—Biological oxidations—GSTP1—urinary bladder cancer	0.000255	0.000848	CbGpPWpGaD
Methoxsalen—CYP1A1—Aryl Hydrocarbon Receptor—KRAS—urinary bladder cancer	0.000254	0.000845	CbGpPWpGaD
Methoxsalen—CYP1A1—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000252	0.000836	CbGpPWpGaD
Methoxsalen—Nausea—Epirubicin—urinary bladder cancer	0.00025	0.000938	CcSEcCtD
Methoxsalen—CYP3A4—renal system—urinary bladder cancer	0.000249	0.0347	CbGeAlD
Methoxsalen—CYP1A1—vagina—urinary bladder cancer	0.000246	0.0342	CbGeAlD
Methoxsalen—Rash—Doxorubicin—urinary bladder cancer	0.000245	0.000921	CcSEcCtD
Methoxsalen—Dermatitis—Doxorubicin—urinary bladder cancer	0.000245	0.00092	CcSEcCtD
Methoxsalen—Headache—Doxorubicin—urinary bladder cancer	0.000244	0.000915	CcSEcCtD
Methoxsalen—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—urinary bladder cancer	0.000242	0.000804	CbGpPWpGaD
Methoxsalen—CYP1A2—Biological oxidations—HPGDS—urinary bladder cancer	0.000242	0.000804	CbGpPWpGaD
Methoxsalen—CYP1A1—PPARA activates gene expression—PPARG—urinary bladder cancer	0.00024	0.000798	CbGpPWpGaD
Methoxsalen—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—urinary bladder cancer	0.000235	0.000781	CbGpPWpGaD
Methoxsalen—CYP1A2—Biological oxidations—GSTT1—urinary bladder cancer	0.000235	0.00078	CbGpPWpGaD
Methoxsalen—CYP1A1—Biological oxidations—GSTM1—urinary bladder cancer	0.000235	0.000779	CbGpPWpGaD
Methoxsalen—CYP3A4—Biological oxidations—NAT2—urinary bladder cancer	0.000234	0.000776	CbGpPWpGaD
Methoxsalen—CYP1A1—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000231	0.000768	CbGpPWpGaD
Methoxsalen—Nausea—Doxorubicin—urinary bladder cancer	0.000231	0.000868	CcSEcCtD
Methoxsalen—CYP1A1—PPARA activates gene expression—CREBBP—urinary bladder cancer	0.000231	0.000767	CbGpPWpGaD
Methoxsalen—CYP3A4—Metapathway biotransformation—NAT2—urinary bladder cancer	0.00023	0.000766	CbGpPWpGaD
Methoxsalen—CYP1A2—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.000226	0.000752	CbGpPWpGaD
Methoxsalen—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—NCOR1—urinary bladder cancer	0.000226	0.000751	CbGpPWpGaD
Methoxsalen—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CREBBP—urinary bladder cancer	0.000226	0.000751	CbGpPWpGaD
Methoxsalen—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—urinary bladder cancer	0.000224	0.000745	CbGpPWpGaD
Methoxsalen—CYP2A13—Metabolism—GSTP1—urinary bladder cancer	0.000218	0.000725	CbGpPWpGaD
Methoxsalen—CYP1A1—Aryl Hydrocarbon Receptor—HRAS—urinary bladder cancer	0.000216	0.000718	CbGpPWpGaD
Methoxsalen—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1A—urinary bladder cancer	0.000212	0.000703	CbGpPWpGaD
Methoxsalen—CYP2A6—Metabolism—GSTZ1—urinary bladder cancer	0.00021	0.000697	CbGpPWpGaD
Methoxsalen—CYP2A13—Metabolism—TYMS—urinary bladder cancer	0.000203	0.000674	CbGpPWpGaD
Methoxsalen—CYP1A2—Aryl Hydrocarbon Receptor—EP300—urinary bladder cancer	0.000201	0.000669	CbGpPWpGaD
Methoxsalen—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—urinary bladder cancer	0.000201	0.000669	CbGpPWpGaD
Methoxsalen—CYP2A13—Metabolism—NCOR1—urinary bladder cancer	0.000201	0.000667	CbGpPWpGaD
Methoxsalen—CYP2A13—Metabolism—GSTM1—urinary bladder cancer	0.000201	0.000667	CbGpPWpGaD
Methoxsalen—CYP3A4—female reproductive system—urinary bladder cancer	0.000199	0.0278	CbGeAlD
Methoxsalen—CYP2A6—Metabolism—GSTO2—urinary bladder cancer	0.000199	0.000661	CbGpPWpGaD
Methoxsalen—CYP2A6—Metabolism—NAT1—urinary bladder cancer	0.000199	0.000661	CbGpPWpGaD
Methoxsalen—CYP1A2—Aryl Hydrocarbon Receptor—SRC—urinary bladder cancer	0.000196	0.00065	CbGpPWpGaD
Methoxsalen—CYP1A2—Aryl Hydrocarbon Receptor Pathway—SRC—urinary bladder cancer	0.000196	0.00065	CbGpPWpGaD
Methoxsalen—CYP2A13—Metabolism—GPX1—urinary bladder cancer	0.000192	0.000638	CbGpPWpGaD
Methoxsalen—CYP2A13—Metabolism—ERCC2—urinary bladder cancer	0.000189	0.000627	CbGpPWpGaD
Methoxsalen—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	0.000187	0.00062	CbGpPWpGaD
Methoxsalen—CYP2A6—Metabolism—UGT2B7—urinary bladder cancer	0.000182	0.000604	CbGpPWpGaD
Methoxsalen—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	0.000181	0.000602	CbGpPWpGaD
Methoxsalen—CYP2A13—Metabolism—MTHFR—urinary bladder cancer	0.000177	0.000589	CbGpPWpGaD
Methoxsalen—CYP1A2—Aryl Hydrocarbon Receptor—MYC—urinary bladder cancer	0.000175	0.000583	CbGpPWpGaD
Methoxsalen—CYP1A2—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000175	0.00058	CbGpPWpGaD
Methoxsalen—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—urinary bladder cancer	0.000172	0.00057	CbGpPWpGaD
Methoxsalen—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—urinary bladder cancer	0.000172	0.00057	CbGpPWpGaD
Methoxsalen—CYP2A6—Metabolism—CYP4B1—urinary bladder cancer	0.000164	0.000544	CbGpPWpGaD
Methoxsalen—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—urinary bladder cancer	0.000163	0.000543	CbGpPWpGaD
Methoxsalen—CYP1A2—Aryl Hydrocarbon Receptor—TNF—urinary bladder cancer	0.000163	0.000543	CbGpPWpGaD
Methoxsalen—CYP1A2—Biological oxidations—GSTP1—urinary bladder cancer	0.000163	0.000541	CbGpPWpGaD
Methoxsalen—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—urinary bladder cancer	0.000162	0.000539	CbGpPWpGaD
Methoxsalen—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—urinary bladder cancer	0.000162	0.000538	CbGpPWpGaD
Methoxsalen—CYP1A2—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.00016	0.000533	CbGpPWpGaD
Methoxsalen—CYP1A1—lymph node—urinary bladder cancer	0.000159	0.0222	CbGeAlD
Methoxsalen—CYP1A1—PPARA activates gene expression—EP300—urinary bladder cancer	0.000157	0.000522	CbGpPWpGaD
Methoxsalen—CYP1A1—Metabolism—GSTZ1—urinary bladder cancer	0.000156	0.000519	CbGpPWpGaD
Methoxsalen—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—CREBBP—urinary bladder cancer	0.000156	0.000517	CbGpPWpGaD
Methoxsalen—CYP2A6—Metabolism—SLC19A1—urinary bladder cancer	0.000155	0.000514	CbGpPWpGaD
Methoxsalen—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—EP300—urinary bladder cancer	0.000154	0.000511	CbGpPWpGaD
Methoxsalen—CYP2A6—Metabolism—PRSS3—urinary bladder cancer	0.000151	0.000501	CbGpPWpGaD
Methoxsalen—CYP1A2—Biological oxidations—GSTM1—urinary bladder cancer	0.00015	0.000497	CbGpPWpGaD
Methoxsalen—CYP1A1—Metabolism—GSTO2—urinary bladder cancer	0.000148	0.000492	CbGpPWpGaD
Methoxsalen—CYP1A1—Metabolism—NAT1—urinary bladder cancer	0.000148	0.000492	CbGpPWpGaD
Methoxsalen—CYP1A2—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000147	0.00049	CbGpPWpGaD
Methoxsalen—CYP1A1—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	0.000146	0.000484	CbGpPWpGaD
Methoxsalen—CYP2A13—Metabolism—PPARG—urinary bladder cancer	0.000144	0.000478	CbGpPWpGaD
Methoxsalen—CYP2A13—Metabolism—CREBBP—urinary bladder cancer	0.000138	0.000459	CbGpPWpGaD
Methoxsalen—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—urinary bladder cancer	0.000138	0.000458	CbGpPWpGaD
Methoxsalen—CYP1A1—Metabolism—UGT2B7—urinary bladder cancer	0.000136	0.00045	CbGpPWpGaD
Methoxsalen—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	0.000126	0.000417	CbGpPWpGaD
Methoxsalen—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000124	0.000411	CbGpPWpGaD
Methoxsalen—CYP1A1—Metabolism—CYP4B1—urinary bladder cancer	0.000122	0.000405	CbGpPWpGaD
Methoxsalen—CYP2A6—Metabolism—TYMP—urinary bladder cancer	0.000121	0.0004	CbGpPWpGaD
Methoxsalen—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	0.000115	0.000383	CbGpPWpGaD
Methoxsalen—CYP1A1—Metabolism—SLC19A1—urinary bladder cancer	0.000115	0.000383	CbGpPWpGaD
Methoxsalen—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000114	0.000378	CbGpPWpGaD
Methoxsalen—CYP2A13—Metabolism—PTGS2—urinary bladder cancer	0.000113	0.000376	CbGpPWpGaD
Methoxsalen—CYP1A1—Metabolism—PRSS3—urinary bladder cancer	0.000112	0.000373	CbGpPWpGaD
Methoxsalen—CYP2A6—Metabolism—NAT2—urinary bladder cancer	0.000109	0.000362	CbGpPWpGaD
Methoxsalen—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—urinary bladder cancer	0.000106	0.000352	CbGpPWpGaD
Methoxsalen—CYP1A2—Metabolism—GSTZ1—urinary bladder cancer	9.97e-05	0.000331	CbGpPWpGaD
Methoxsalen—CYP2A13—Metabolism—PTEN—urinary bladder cancer	9.87e-05	0.000328	CbGpPWpGaD
Methoxsalen—CYP1A2—Metabolism—GSTO2—urinary bladder cancer	9.45e-05	0.000314	CbGpPWpGaD
Methoxsalen—CYP1A2—Metabolism—NAT1—urinary bladder cancer	9.45e-05	0.000314	CbGpPWpGaD
Methoxsalen—CYP2A13—Metabolism—EP300—urinary bladder cancer	9.41e-05	0.000313	CbGpPWpGaD
Methoxsalen—CYP2A6—Metabolism—RRM2—urinary bladder cancer	9.41e-05	0.000313	CbGpPWpGaD
Methoxsalen—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	9.29e-05	0.000309	CbGpPWpGaD
Methoxsalen—CYP1A1—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	9e-05	0.000299	CbGpPWpGaD
Methoxsalen—CYP1A1—Metabolism—TYMP—urinary bladder cancer	8.98e-05	0.000298	CbGpPWpGaD
Methoxsalen—CYP2A6—Metabolism—HPGDS—urinary bladder cancer	8.71e-05	0.000289	CbGpPWpGaD
Methoxsalen—CYP2A6—Metabolism—ENO2—urinary bladder cancer	8.71e-05	0.000289	CbGpPWpGaD
Methoxsalen—CYP1A2—Metabolism—UGT2B7—urinary bladder cancer	8.64e-05	0.000287	CbGpPWpGaD
Methoxsalen—CYP1A1—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	8.62e-05	0.000286	CbGpPWpGaD
Methoxsalen—CYP2A6—Metabolism—GSTT1—urinary bladder cancer	8.45e-05	0.000281	CbGpPWpGaD
Methoxsalen—CYP1A1—Metabolism—NAT2—urinary bladder cancer	8.12e-05	0.00027	CbGpPWpGaD
Methoxsalen—CYP1A2—Metabolism—CYP4B1—urinary bladder cancer	7.78e-05	0.000258	CbGpPWpGaD
Methoxsalen—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	7.69e-05	0.000256	CbGpPWpGaD
Methoxsalen—CYP1A2—Metabolism—SLC19A1—urinary bladder cancer	7.35e-05	0.000244	CbGpPWpGaD
Methoxsalen—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	7.29e-05	0.000242	CbGpPWpGaD
Methoxsalen—CYP3A4—Metabolism—NAT1—urinary bladder cancer	7.29e-05	0.000242	CbGpPWpGaD
Methoxsalen—CYP1A2—Metabolism—PRSS3—urinary bladder cancer	7.16e-05	0.000238	CbGpPWpGaD
Methoxsalen—CYP2A6—Metabolism—NQO1—urinary bladder cancer	7.02e-05	0.000233	CbGpPWpGaD
Methoxsalen—CYP1A1—Metabolism—RRM2—urinary bladder cancer	7.01e-05	0.000233	CbGpPWpGaD
Methoxsalen—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	6.67e-05	0.000222	CbGpPWpGaD
Methoxsalen—CYP1A1—Metabolism—HPGDS—urinary bladder cancer	6.49e-05	0.000216	CbGpPWpGaD
Methoxsalen—CYP1A1—Metabolism—ENO2—urinary bladder cancer	6.49e-05	0.000216	CbGpPWpGaD
Methoxsalen—CYP1A1—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	6.45e-05	0.000214	CbGpPWpGaD
Methoxsalen—CYP1A1—Metabolism—GSTT1—urinary bladder cancer	6.3e-05	0.000209	CbGpPWpGaD
Methoxsalen—CYP1A1—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	6.2e-05	0.000206	CbGpPWpGaD
Methoxsalen—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	6.01e-05	0.000199	CbGpPWpGaD
Methoxsalen—CYP2A6—Metabolism—GSTP1—urinary bladder cancer	5.86e-05	0.000195	CbGpPWpGaD
Methoxsalen—CYP1A2—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	5.74e-05	0.000191	CbGpPWpGaD
Methoxsalen—CYP1A2—Metabolism—TYMP—urinary bladder cancer	5.72e-05	0.00019	CbGpPWpGaD
Methoxsalen—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	5.67e-05	0.000188	CbGpPWpGaD
Methoxsalen—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	5.53e-05	0.000184	CbGpPWpGaD
Methoxsalen—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	5.5e-05	0.000183	CbGpPWpGaD
Methoxsalen—CYP2A6—Metabolism—TYMS—urinary bladder cancer	5.45e-05	0.000181	CbGpPWpGaD
Methoxsalen—CYP2A6—Metabolism—NCOR1—urinary bladder cancer	5.38e-05	0.000179	CbGpPWpGaD
Methoxsalen—CYP2A6—Metabolism—GSTM1—urinary bladder cancer	5.38e-05	0.000179	CbGpPWpGaD
Methoxsalen—CYP1A1—Metabolism—NQO1—urinary bladder cancer	5.23e-05	0.000174	CbGpPWpGaD
Methoxsalen—CYP1A2—Metabolism—NAT2—urinary bladder cancer	5.18e-05	0.000172	CbGpPWpGaD
Methoxsalen—CYP2A6—Metabolism—GPX1—urinary bladder cancer	5.15e-05	0.000171	CbGpPWpGaD
Methoxsalen—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	5.08e-05	0.000169	CbGpPWpGaD
Methoxsalen—CYP2A6—Metabolism—ERCC2—urinary bladder cancer	5.06e-05	0.000168	CbGpPWpGaD
Methoxsalen—CYP2A6—Metabolism—MTHFR—urinary bladder cancer	4.76e-05	0.000158	CbGpPWpGaD
Methoxsalen—CYP1A2—Metabolism—RRM2—urinary bladder cancer	4.47e-05	0.000148	CbGpPWpGaD
Methoxsalen—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	4.43e-05	0.000147	CbGpPWpGaD
Methoxsalen—CYP3A4—Metabolism—TYMP—urinary bladder cancer	4.42e-05	0.000147	CbGpPWpGaD
Methoxsalen—CYP1A1—Metabolism—GSTP1—urinary bladder cancer	4.36e-05	0.000145	CbGpPWpGaD
Methoxsalen—CYP1A1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	4.22e-05	0.00014	CbGpPWpGaD
Methoxsalen—CYP1A2—Metabolism—HPGDS—urinary bladder cancer	4.14e-05	0.000137	CbGpPWpGaD
Methoxsalen—CYP1A2—Metabolism—ENO2—urinary bladder cancer	4.14e-05	0.000137	CbGpPWpGaD
Methoxsalen—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	4.11e-05	0.000137	CbGpPWpGaD
Methoxsalen—CYP1A1—Metabolism—TYMS—urinary bladder cancer	4.06e-05	0.000135	CbGpPWpGaD
Methoxsalen—CYP1A2—Metabolism—GSTT1—urinary bladder cancer	4.01e-05	0.000133	CbGpPWpGaD
Methoxsalen—CYP1A1—Metabolism—GSTM1—urinary bladder cancer	4.01e-05	0.000133	CbGpPWpGaD
Methoxsalen—CYP1A1—Metabolism—NCOR1—urinary bladder cancer	4.01e-05	0.000133	CbGpPWpGaD
Methoxsalen—CYP3A4—Metabolism—NAT2—urinary bladder cancer	4e-05	0.000133	CbGpPWpGaD
Methoxsalen—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	3.95e-05	0.000131	CbGpPWpGaD
Methoxsalen—CYP2A6—Metabolism—PPARG—urinary bladder cancer	3.86e-05	0.000128	CbGpPWpGaD
Methoxsalen—CYP1A1—Metabolism—GPX1—urinary bladder cancer	3.84e-05	0.000128	CbGpPWpGaD
Methoxsalen—CYP1A1—Metabolism—ERCC2—urinary bladder cancer	3.77e-05	0.000125	CbGpPWpGaD
Methoxsalen—CYP2A6—Metabolism—CREBBP—urinary bladder cancer	3.71e-05	0.000123	CbGpPWpGaD
Methoxsalen—CYP1A1—Metabolism—MTHFR—urinary bladder cancer	3.54e-05	0.000118	CbGpPWpGaD
Methoxsalen—CYP3A4—Metabolism—RRM2—urinary bladder cancer	3.45e-05	0.000115	CbGpPWpGaD
Methoxsalen—CYP1A2—Metabolism—NQO1—urinary bladder cancer	3.34e-05	0.000111	CbGpPWpGaD
Methoxsalen—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	3.24e-05	0.000108	CbGpPWpGaD
Methoxsalen—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	3.19e-05	0.000106	CbGpPWpGaD
Methoxsalen—CYP3A4—Metabolism—ENO2—urinary bladder cancer	3.19e-05	0.000106	CbGpPWpGaD
Methoxsalen—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	3.1e-05	0.000103	CbGpPWpGaD
Methoxsalen—CYP2A6—Metabolism—PTGS2—urinary bladder cancer	3.03e-05	0.000101	CbGpPWpGaD
Methoxsalen—CYP1A1—Metabolism—PPARG—urinary bladder cancer	2.87e-05	9.55e-05	CbGpPWpGaD
Methoxsalen—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.82e-05	9.38e-05	CbGpPWpGaD
Methoxsalen—CYP1A2—Metabolism—GSTP1—urinary bladder cancer	2.78e-05	9.24e-05	CbGpPWpGaD
Methoxsalen—CYP1A1—Metabolism—CREBBP—urinary bladder cancer	2.76e-05	9.17e-05	CbGpPWpGaD
Methoxsalen—CYP1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.69e-05	8.94e-05	CbGpPWpGaD
Methoxsalen—CYP2A6—Metabolism—PTEN—urinary bladder cancer	2.65e-05	8.79e-05	CbGpPWpGaD
Methoxsalen—CYP1A2—Metabolism—TYMS—urinary bladder cancer	2.59e-05	8.59e-05	CbGpPWpGaD
Methoxsalen—CYP3A4—Metabolism—NQO1—urinary bladder cancer	2.57e-05	8.55e-05	CbGpPWpGaD
Methoxsalen—CYP1A2—Metabolism—NCOR1—urinary bladder cancer	2.56e-05	8.49e-05	CbGpPWpGaD
Methoxsalen—CYP1A2—Metabolism—GSTM1—urinary bladder cancer	2.56e-05	8.49e-05	CbGpPWpGaD
Methoxsalen—CYP2A6—Metabolism—EP300—urinary bladder cancer	2.52e-05	8.38e-05	CbGpPWpGaD
Methoxsalen—CYP1A2—Metabolism—GPX1—urinary bladder cancer	2.45e-05	8.13e-05	CbGpPWpGaD
Methoxsalen—CYP1A2—Metabolism—ERCC2—urinary bladder cancer	2.4e-05	7.99e-05	CbGpPWpGaD
Methoxsalen—CYP1A1—Metabolism—PTGS2—urinary bladder cancer	2.26e-05	7.51e-05	CbGpPWpGaD
Methoxsalen—CYP1A2—Metabolism—MTHFR—urinary bladder cancer	2.26e-05	7.51e-05	CbGpPWpGaD
Methoxsalen—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	2.15e-05	7.13e-05	CbGpPWpGaD
Methoxsalen—CYP3A4—Metabolism—TYMS—urinary bladder cancer	2e-05	6.63e-05	CbGpPWpGaD
Methoxsalen—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	1.97e-05	6.56e-05	CbGpPWpGaD
Methoxsalen—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	1.97e-05	6.56e-05	CbGpPWpGaD
Methoxsalen—CYP1A1—Metabolism—PTEN—urinary bladder cancer	1.97e-05	6.55e-05	CbGpPWpGaD
Methoxsalen—CYP3A4—Metabolism—GPX1—urinary bladder cancer	1.89e-05	6.28e-05	CbGpPWpGaD
Methoxsalen—CYP1A1—Metabolism—EP300—urinary bladder cancer	1.88e-05	6.25e-05	CbGpPWpGaD
Methoxsalen—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	1.86e-05	6.16e-05	CbGpPWpGaD
Methoxsalen—CYP1A2—Metabolism—PPARG—urinary bladder cancer	1.83e-05	6.09e-05	CbGpPWpGaD
Methoxsalen—CYP1A2—Metabolism—CREBBP—urinary bladder cancer	1.76e-05	5.85e-05	CbGpPWpGaD
Methoxsalen—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	1.74e-05	5.79e-05	CbGpPWpGaD
Methoxsalen—CYP1A2—Metabolism—PTGS2—urinary bladder cancer	1.44e-05	4.79e-05	CbGpPWpGaD
Methoxsalen—CYP3A4—Metabolism—PPARG—urinary bladder cancer	1.41e-05	4.7e-05	CbGpPWpGaD
Methoxsalen—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	1.36e-05	4.51e-05	CbGpPWpGaD
Methoxsalen—CYP1A2—Metabolism—PTEN—urinary bladder cancer	1.26e-05	4.18e-05	CbGpPWpGaD
Methoxsalen—CYP1A2—Metabolism—EP300—urinary bladder cancer	1.2e-05	3.98e-05	CbGpPWpGaD
Methoxsalen—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	1.11e-05	3.7e-05	CbGpPWpGaD
Methoxsalen—CYP3A4—Metabolism—PTEN—urinary bladder cancer	9.7e-06	3.22e-05	CbGpPWpGaD
Methoxsalen—CYP3A4—Metabolism—EP300—urinary bladder cancer	9.25e-06	3.07e-05	CbGpPWpGaD
